FTRE1 Stock Chart & Stats
$373.00
$0.00(0.00%)
At close: 4:00 PM EDT
$373.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$373.00 - $373.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$32.40B
Enterprise Value$2.60K
Total Cash (Recent Filing)$168.60M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Nov 05, 2026EPS Estimate
3.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding95,100,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$379.84Price Target Upside1.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)14.27
Revenue Forecast (FY)$45.21B
Bulls Say, Bears Say
Bulls Say
Commercial MomentumStrong bookings and a backlog substantially above current annual revenue provide visibility into future clinical services work. Multiple quarters with book-to-bill above 1.0x indicate demand is replenishing executed projects, supporting revenue conversion and utilization over the next several quarters.
Cash Generation And DeleveragingPositive operating and free cash flow give Fortrea internal funding capacity despite accounting losses, while debt reduction and lower interest expense improve financial flexibility. Sustained cash generation can support liquidity, continued deleveraging, and investment in operations without relying solely on external capital.
Cost Efficiency And OutlookBroad cost reductions, including lower direct costs and SG&A, are already translating into stronger adjusted EBITDA and a higher full-year outlook. If these savings persist while commercial activity converts from backlog, they can provide a durable foundation for margin recovery and earnings improvement.
Bears Say
Persistent UnprofitabilityFortrea remains loss-making on a GAAP basis and has experienced substantial gross-margin compression, limiting the earnings produced by each dollar of revenue. This weak profitability makes recovery dependent on sustained cost savings, better study mix, and improved execution rather than growth alone.
Customer ConcentrationA high share of revenue tied to a small group of customers increases the effect of any large-account slowdown, repricing, cancellation, or delayed study activity. Concentration can therefore create persistent revenue and utilization volatility even when total industry outsourcing demand remains healthy.
Elevated LeverageAlthough Fortrea has reduced debt, leverage remains elevated relative to its current earnings profile and equity has fallen substantially. This constrains financial flexibility, leaves less room to absorb renewed operating weakness, and makes continued positive cash generation important for further balance-sheet repair.
Fortrea Holdings Inc. News
FTRE1 FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $373.00 and its highest was $373.00 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $32.40B.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 49 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on Jul 29, 2026. The company reported $3.915 earnings per share for the quarter, beating the consensus estimate of $3.064 by $0.851.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 3.64.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 95,100,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $3.915 in its last earnings report, beating expectations of $3.064. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in MX:FTRE1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$379.84 (1.83% Upside)
$379.84 (1.83% Upside)
Blogger Sentiment
Bullish
MX:FTRE1 Sentiment 67%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
FTRE1 Company Deck
FTRE1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted substantial commercial momentum (bookings up, net new business +19% H1), improved profitability metrics (adjusted EBITDA growth, cost savings, SG&A reduction), stronger cash generation and an upgraded full-year guidance, alongside early operational wins from FIT/AI and CPS strength. Key risks discussed include a modest YoY revenue decline driven by pass-through/FSP dynamics, elevated customer concentration, a CFO transition related to a restrictive covenant matter, and the early-stage nature of AI benefits. On balance, the positive operational, commercial and financial traction and the guidance raise outweigh the listed challenges.View all MX:FTRE1 earnings summariesFTRE1 Stock 12 Month Forecast
Average Price Target
$379.84
▲(1.83% Upside)
Technical Analysis
Maravai Lifesciences Holdings
―
AbCellera Biologics
―
Recursion Pharmaceuticals
―
MBX Biosciences, Inc.
―
Generate Biomedicines, Inc.
―